Aclaris Therapeutics, Inc.

NASDAQ:ACRS

2.92 (USD) • At close December 26, 2024
Bedrijfsnaam Aclaris Therapeutics, Inc.
Symbool ACRS
Munteenheid USD
Prijs 2.915
Beurswaarde 208,221,074
Dividendpercentage 0%
52-weken bereik 0.856 - 5.17
Industrie Diagnostics & Research
Sector Healthcare
CEO Dr. Douglas J. Manion Frcp(C), M.D.
Website https://www.aclaristx.com

An error occurred while fetching data.

Over Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research

Vergelijkbare Aandelen

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

6 USD

Kura Oncology, Inc. logo

Kura Oncology, Inc.

KURA

8.98 USD

FibroGen, Inc. logo

FibroGen, Inc.

FGEN

0.579 USD

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

1.7 USD

Mirum Pharmaceuticals, Inc. logo

Mirum Pharmaceuticals, Inc.

MIRM

42.03 USD

Cutera, Inc. logo

Cutera, Inc.

CUTR

0.319 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

12.925 USD

Avid Bioservices, Inc. logo

Avid Bioservices, Inc.

CDMO

12.28 USD

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

16.81 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)